0001104659-22-006977.txt : 20220124 0001104659-22-006977.hdr.sgml : 20220124 20220124170519 ACCESSION NUMBER: 0001104659-22-006977 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220124 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220124 DATE AS OF CHANGE: 20220124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC. CENTRAL INDEX KEY: 0001287098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 522210438 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40674 FILM NUMBER: 22550191 BUSINESS ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 301-517-5556 MAIL ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: MAXCYTE INC DATE OF NAME CHANGE: 20040415 8-K 1 tm224229d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 24, 2022

MaxCyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-40674	52-2210438
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

22 Firstfield Road, Suite 110

Gaithersburg, Maryland 20878

(Address of principal executive offices, including zip code)

(301) 944-1700

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.01 par value

MXCT

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial account standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On January 24, 2022, MaxCyte, Inc. (the “Company”) issued a press release announcing preliminary estimated revenue results for the Company’s fiscal quarter and year ended December 31, 2021. This press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibits are not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description

99.1		Press Release, dated January 24, 2022
104		Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MaxCyte, Inc.

Dated: January 24, 2022	By:	/s/ Doug Doerfler
		Doug Doerfler
		President and Chief Executive Officer

EX-99.1 2 tm224229d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results

·

Fourth quarter 2021 revenue expected to be greater than $10 million

·

Full year 2021 revenue expected to be greater than $33.7 million

·

Installed base of greater than 500 instruments

·

15 SPLs, covering more than 95 programs, of which over 15% have entered the clinic

·

Precommercial milestone revenue potential from our SPL programs exceeds $1.25 billion

GAITHERSBURG, MD., January 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today provides a preliminary update on revenue results for the fourth quarter and full year 2021.

Preliminary Unaudited Fourth Quarter 2021 and Full Year Revenue

Management expects total revenue for the fourth quarter of 2021 to be more than $10.0 million, up from $8.5 million of total revenue in the fourth quarter of 2020, reflecting growth of at least 17% in total revenue and at least 37% in core business revenue.

MaxCyte’s revenue for the fourth quarter of 2021 was derived from its core business, which is defined as sales or leases of instruments, sales of single-use disposables, and sales of consumables (buffer) to the cell therapy and drug discovery markets.

MaxCyte also generates revenue under Strategic Platform License agreements (SPLs) with cell therapy developers, such as precommercial milestone payments. These revenues are categorized as program-related revenue and are excluded from core business revenue.

Preliminary revenue for the full year ended December 31, 2021 is expected to be more than $33.7 million, up from $26.2 million in full year 2020, reflecting growth of at least 28% in total revenue and at least 36% in core business revenue. Revenue for the full year ended December 31, 2021 includes $2.5 million of program-related revenue, compared to $3.3 million of program-related revenue in 2020.

MaxCyte ended the year with 15 SPLs, including 4 SPLs added during 2021: Nkarta, Inc., Myeloid Therapeutics, Celularity, Inc. and Sana Biotechnology, Inc.

Doug Doerfler, President and CEO of MaxCyte said: “We are proud of our performance in the fourth quarter as well as the full year, which has been a year of key achievements for the company. This includes raising $257.2 million in gross equity proceeds, the completion of an IPO in the United States and commencement of trading in our common stock on the Nasdaq, continuing significant organic growth in our core business, and our ongoing success in signing SPLs with innovative cell therapy developers. We are also excited to confirm that our ExPERT^™ VLx instrument became available for sale at the end of December.”

“We remain optimistic about the potential for our SPLs to generate meaningful revenue over the next 12 to 18 months and beyond. Our partners continue to achieve clinical success – particularly in moving their next-generation product candidates into pivotal trials. We also see the potential for several IND filings by our SPL customers for novel ex vivo engineered cell therapies this year. Finally, we continue to benefit from the ongoing investment in the ex vivo engineered cell therapy space. As a result, we believe our SPL pipeline remains as robust and diverse as ever. We look forward to a strong 2022.”

MaxCyte’s fourth quarter and full year 2021 financial results presented in this release are preliminary and unaudited and are subject to revision based on the completion of MaxCyte’s normal quarter and year-end process and year-end audit. As a result, these preliminary results may be different from the actual results that will be reflected in MaxCyte’s consolidated financial statements for the quarter and year ended December 31, 2021, which are expected to be released by the end of March 2022.

In addition to revenue, management regularly reviews key business metrics to evaluate MaxCyte’s business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. As of the dates presented, these key metrics were as follows:

		As of December 31,
		2019			2020*			2021
Installed base of instruments (sold or leased)		>320			>400			>500
Number of SPLs		8			12			15
Total number of licensed clinical programs (SPLs only)		>55			>75			>95
Total number of licensed clinical programs under SPLs that have entered the clinic **		>5%			>15%			>15%
Total potential pre-commercial milestones under SPLs		>$650 million			>$950 million			>$1.25 billion

* Amounts presented as of December 31, 2020 give effect to one SPL entered into and additional INDs cleared in January 2021.

** Number of licensed clinical programs under SPLs are by number of product candidates and not by indication.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation^® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT^™platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. With the addition of the VLx^™, the ExPERT platform now includes: four instruments, the ATx^™, STx^™, GTx^™, and VLx^™; and proprietary processing assemblies or disposables, and software protocols -- all supported by a robust global intellectual property portfolio and clinical support via our FDA Master File/Technical Files.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our expected revenue for the quarter and year ended December 31, 2021, expansion of and revenue from our SPLs and the progression of our customers’ programs into and through clinical trials. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with the impact of COVID-19 on our operations; the timing of our customers’ ongoing and planned clinical trials; the adequacy of our cash resources and availability of financing on commercially reasonable terms; and general market and economic conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in our final prospectus dated July 29, 2021, filed with the Securities and Exchange Commission on July 30, 2021, as well as discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available under the “SEC filings” page of the Investors section of our website at http://investors.maxcyte.com. Any forward-looking statements represent our views only as of the date of this press release and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@consilium-comms.com

EX-101.SCH 3 mxct-20220124.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mxct-20220124_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mxct-20220124_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jan. 24, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 24, 2022
Entity File Number	001-40674
Entity Registrant Name	MaxCyte, Inc.
Entity Central Index Key	0001287098
Entity Tax Identification Number	52-2210438
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	22 Firstfield Road
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Gaithersburg
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20878
City Area Code	301
Local Phone Number	944-1700
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	MXCT
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 7 tm224229d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001287098 2022-01-24 2022-01-24 iso4217:USD shares iso4217:USD shares 0001287098 false 8-K 2022-01-24 MaxCyte, Inc. DE 001-40674 52-2210438 22 Firstfield Road Suite 110 Gaithersburg MD 20878 301 944-1700 false false false false Common Stock, $0.01 par value MXCT NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://maxcyte.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm224229d1_8k.htm mxct-20220124.xsd mxct-20220124_lab.xml mxct-20220124_pre.xml tm224229d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm224229d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm224229d1_8k.htm" ] }, "labelLink": { "local": [ "mxct-20220124_lab.xml" ] }, "presentationLink": { "local": [ "mxct-20220124_pre.xml" ] }, "schema": { "local": [ "mxct-20220124.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "MXCT", "nsuri": "http://maxcyte.com/20220124", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm224229d1_8k.htm", "contextRef": "From2022-01-24to2022-01-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://maxcyte.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm224229d1_8k.htm", "contextRef": "From2022-01-24to2022-01-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://maxcyte.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001104659-22-006977-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-006977-xbrl.zip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